Mobile

A study to investigate the safety and efficacy of a six month oral treatment with a twice daily dose of BAY 1142524 in comparison to placebo in patients with reduced left-ventricular ejection fraction...

Mise à jour : Il y a 4 ans
Référence : EUCTR2016-002167-33

A study to investigate the safety and efficacy of a six month oral treatment with a twice daily dose of BAY 1142524 in comparison to placebo in patients with reduced left-ventricular ejection fraction after acute myocardial infarction. Studie hodnotící bezpečnost a účinnost 6měsíční léčby přípravkem BAY 1142524 podávaného perorálně dvakrát denně, v porovnání s placebem, u pacientů se sníženou ejekční frakcí levé komory po akutním infarktu myokardu

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to determine efficacy of BAY 1142524 by investigating the changes in LVEF, EDVI, and ESVI from baseline to 6 months after treatment with 25 mg of BAY 1142524 BID in comparison to placebo and on top of standard of care as measured by cardiac MRI

Critère d'inclusion

  • Left-ventricular dysfunction after acute myocardial infarction

Liens